Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has shared an update.
Shanghai Junshi Biosciences Co., Ltd. announced that its wholly-owned subsidiary, Suzhou Union Biopharm Co., Ltd., has successfully passed an unannounced FDA on-site inspection for Current Good Manufacturing Practice (CGMP) compliance. This achievement marks the second successful FDA inspection for Suzhou Union, reinforcing the company’s high production standards and supporting its expansion strategy in the U.S. market. The successful inspection is expected to positively impact the company’s operations and strengthen its position in the global pharmaceutical industry.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative drugs, particularly in the field of oncology. The company is known for its product, Toripalimab injection, and has a significant presence in various international markets, including the United States, Europe, and Asia.
Average Trading Volume: 11,766,082
Technical Sentiment Signal: Buy
Current Market Cap: HK$39.23B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.